|
|
|
|
|
226
|
Triple Analysis: Pancreatic Cancer, Angiogenesis and Peptides |
Jun 2010 |
$5,003.00 |
|
This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Pancreatic Cancer), one mechanism/target/effect area (Angiogenesis) and one compound specific area (Peptides). Each of these three individual parts is evaluated according
more...
Published by: BioSeeker Group AB
|
|
|
227
|
Triple Analysis: Melanoma, Pancreatic Cancer and Peptides |
Jun 2010 |
$5,003.00 |
|
This triple analysis focuses on cancer drug development strategies in both Melanoma and Pancreatic Cancer and by the compound strategy of Peptides. Each of these three individual parts is evaluated according to standardized criteria in
more...
Published by: BioSeeker Group AB
|
|
|
228
|
Triple Analysis: Melanoma, Prostate Cancer and Peptides |
Jun 2010 |
$5,003.00 |
|
This triple analysis focuses on cancer drug development strategies in both Melanoma and Prostate Cancer and by the compound strategy of Peptides. Each of these three individual parts is evaluated according to standardized criteria in
more...
Published by: BioSeeker Group AB
|
|
|
229
|
Triple Analysis: Pancreatic Cancer, Apoptosis and Peptides |
Jun 2010 |
$5,003.00 |
|
This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Pancreatic Cancer), one mechanism/target/effect area (Apoptosis) and one compound specific area (Peptides). Each of these three individual parts is evaluated according
more...
Published by: BioSeeker Group AB
|
|
|
230
|
Triple Analysis: Melanoma, Apoptosis and Peptides |
Jun 2010 |
$5,003.00 |
|
This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Melanoma), one mechanism/target/effect area (Apoptosis) and one compound specific area (Peptides). Each of these three individual parts is evaluated according to
more...
Published by: BioSeeker Group AB
|
|
|
231
|
Triple Analysis: Melanoma, Angiogenesis and Peptides |
Jun 2010 |
$5,003.00 |
|
This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Melanoma), one mechanism/target/effect area (Angiogenesis) and one compound specific area (Peptides). Each of these three individual parts is evaluated according to
more...
Published by: BioSeeker Group AB
|
|
|
232
|
Triple Analysis: Melanoma, Cancer Vaccines and Peptides |
Jun 2010 |
$5,003.00 |
|
This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Melanoma), one mechanism/target/effect area (Cancer Vaccines) and one compound specific area (Peptides). Each of these three individual parts is evaluated according
more...
Published by: BioSeeker Group AB
|
|
|
233
|
Triple Analysis: Pancreatic Cancer, Prostate Cancer and Peptides |
Jun 2010 |
$5,003.00 |
|
This triple analysis focuses on cancer drug development strategies in both Pancreatic Cancer and Prostate Cancer and by the compound strategy of Peptides. Each of these three individual parts is evaluated according to standardized criteria
more...
Published by: BioSeeker Group AB
|
|
|
234
|
Triple Analysis: Protein Kinase Inhibitors, Antibodies and Peptides |
Jun 2010 |
$5,003.00 |
|
This triple analysis focuses on cancer drug development strategies by the mechanism/target/effect of Protein Kinase Inhibitors and by the two compound strategies of Antibodies and Peptides. Each of these three individual parts is evaluated according
more...
Published by: BioSeeker Group AB
|
|
|
235
|
Triple Analysis: Angiogenesis, Antibodies and Peptides |
Jun 2010 |
$5,003.00 |
|
This triple analysis focuses on cancer drug development strategies by the mechanism/target/effect of Angiogenesis and by the two compound strategies of Antibodies and Peptides. Each of these three individual parts is evaluated according to standardized
more...
Published by: BioSeeker Group AB
|
|
|
236
|
Triple Analysis: Angiogenesis, Protein Kinase Inhibitors and Peptides |
Jun 2010 |
$5,003.00 |
|
This triple analysis focuses on cancer drug development strategies by the two mechanism/target/effect areas of Angiogenesis and Protein Kinase Inhibitors and by the compound strategy of Peptides. Each of these three individual parts is evaluated
more...
Published by: BioSeeker Group AB
|
|
|
237
|
Analytical Tool - Peptides in Oncology |
Jun 2010 |
$4,495.00 |
|
Analytical Tool- Peptides in Oncology" offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in peptide drug development for the treatment of cancer. It is at the same time
more...
Published by: BioSeeker Group AB
|
|
|
238
|
Triple Analysis: Breast Cancer, Pancreatic Cancer and Peptides |
Jun 2010 |
$5,003.00 |
|
This triple analysis focuses on cancer drug development strategies in both Breast Cancer and Pancreatic Cancer and by the compound strategy of Peptides. Each of these three individual parts is evaluated according to standardized criteria
more...
Published by: BioSeeker Group AB
|
|
|
239
|
Commercializing Peptides in Oncology: A Decision Support Tool for Optimizing the Pipeline |
Jun 2010 |
$3,553.00 |
|
This report comprises defined and up to date development strategies for 145 cancer peptide drugs within the portfolio of 103 investigators, from Ceased to Marketed. The report extensively analyses 125 identified targets of peptide drugs,
more...
Published by: BioSeeker Group AB
|
|
|
240
|
Triple Analysis: Leukemia, Lung Cancer and Peptides |
Jun 2010 |
$5,003.00 |
|
This triple analysis focuses on cancer drug development strategies in both Leukemia and Lung Cancer and by the compound strategy of Peptides. Each of these three individual parts is evaluated according to standardized criteria in
more...
Published by: BioSeeker Group AB
|
|
|
241
|
Triple Analysis: Colorectal Cancer, Antibodies and Peptides |
Jun 2010 |
$5,003.00 |
|
This triple analysis focuses on cancer drug development strategies in Colorectal Cancer and by the two compound strategies of Antibodies and Peptides. Each of these three individual parts is evaluated according to standardized criteria in
more...
Published by: BioSeeker Group AB
|
|
|
242
|
Triple Analysis: Leukemia, Prostate Cancer and Peptides |
Jun 2010 |
$5,003.00 |
|
This triple analysis focuses on cancer drug development strategies in both Leukemia and Prostate Cancer and by the compound strategy of Peptides. Each of these three individual parts is evaluated according to standardized criteria in
more...
Published by: BioSeeker Group AB
|
|
|
243
|
Triple Analysis: Leukemia, Apoptosis and Peptides |
Jun 2010 |
$5,003.00 |
|
This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Leukemia), one mechanism/target/effect area (Apoptosis) and one compound specific area (Peptides). Each of these three individual parts is evaluated according to
more...
Published by: BioSeeker Group AB
|
|
|
244
|
Triple Analysis: Leukemia, Angiogenesis and Peptides |
Jun 2010 |
$5,003.00 |
|
This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Leukemia), one mechanism/target/effect area (Angiogenesis) and one compound specific area (Peptides). Each of these three individual parts is evaluated according to
more...
Published by: BioSeeker Group AB
|
|
|
245
|
Triple Analysis: Lymphoma, Cancer Vaccines and Peptides |
Jun 2010 |
$5,003.00 |
|
This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Lymphoma), one mechanism/target/effect area (Cancer Vaccines) and one compound specific area (Peptides). Each of these three individual parts is evaluated according
more...
Published by: BioSeeker Group AB
|
|
|
246
|
Triple Analysis: Leukemia, Cancer Vaccines and Peptides |
Jun 2010 |
$5,003.00 |
|
This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Leukemia), one mechanism/target/effect area (Cancer Vaccines) and one compound specific area (Peptides). Each of these three individual parts is evaluated according
more...
Published by: BioSeeker Group AB
|
|
|
247
|
Triple Analysis: Colorectal Cancer, Protein Kinase Inhibitors and Peptides |
Jun 2010 |
$5,003.00 |
|
This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Colorectal Cancer), one mechanism/target/effect area (Protein Kinase Inhibitors) and one compound specific area (Peptides). Each of these three individual parts is
more...
Published by: BioSeeker Group AB
|
|
|
248
|
Triple Analysis: Colorectal Cancer, Angiogenesis and Peptides |
Jun 2010 |
$5,003.00 |
|
This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Colorectal Cancer), one mechanism/target/effect area (Angiogenesis) and one compound specific area (Peptides). Each of these three individual parts is evaluated according
more...
Published by: BioSeeker Group AB
|
|
|
249
|
Triple Analysis: Leukemia, Protein Kinase Inhibitors and Peptides |
Jun 2010 |
$5,003.00 |
|
This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Leukemia), one mechanism/target/effect area (Protein Kinase Inhibitors) and one compound specific area (Peptides). Each of these three individual parts is evaluated
more...
Published by: BioSeeker Group AB
|
|
|
250
|
Triple Analysis: Breast Cancer, Lung Cancer and Peptides |
Jun 2010 |
$5,003.00 |
|
This triple analysis focuses on cancer drug development strategies in both Breast Cancer and Lung Cancer and by the compound strategy of Peptides. Each of these three individual parts is evaluated according to standardized criteria
more...
Published by: BioSeeker Group AB
|
|
|
|
|
|
0 items
